 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
equity interest held by Allegiance Equity Corporation (TSXV: ANQ)) is pleased to announce that its
licensee, Apollo Pharmaceuticals, has conducted preclinical research studies to characterize the
Pharmacological profile of Relieva(R), a topical preparation containing Psorberine in Novasome(R), a
proprietary liposome formulation. The in vitro studies to specifically determine the immunoregulatory
effects of Psorberine show that:
1. It inhibits the growth of bacteria.
2. It inhibits the release of the pro-inflammatory cytokines such as IL-8,
TNF-alpha and IL-1beta, as well as the inflammatory cytokine IL-2. This
effect of Psorberine may contribute to its anti-inflammatory activity.
3. It inhibits the chemotaxis of T cells toward chemokines. An activity
that is important for any anti-inflammatory compound.
The anti-inflammatory and antibacterial activity of psorberine suggests that it might be useful in
patients with Atopic Dermatitis.
To determine the efficacy and tolerability of Relieva(R) in adult patients with Atopic Dermatitis, an
open label study was conducted in the USA. Forty two patients were enrolled in the 12 week trial. The
study was very successful and the final results will be available as soon as the analysis is completed.
Psoriasis is an incurable skin disease that is characterized by rapid cell proliferation and inflammation.
It affects 3% of the world's population, and The Medical Technology Stock Letter estimates the global
market for psoriasis therapies to exceed $7 billion annually. Current treatments are primarily topical
creams and ointments, most of which have side effects or safety concerns that preclude long-term
use.
A major new clinical trial accepted and published in the American Journal of Therapeutics (American
Journal of Therapeutics 13, pp.121-126 (2006)) recognized that Prime's Relieva(R) is a major
breakthrough in the treatment of psoriasis providing effective relief without side effects. For further
information visit www.relievaforpsoriasis.com
The TSX Venture Exchange has not reviewed and does not accept responsibility FOR THE
ADEQUACY OR ACCURACY FOR THIS PRESS RELEASE, WHICH HAS BEEN PREPARED BY
MANAGEMENT.
For further information on Allegiance Equity Corporation, contact David Solomon, President, by
telephone at 416-944-2840 or dsolomon@primepharmaceutical.com or visit
www.allegianceequity.com.
This press release was issued through GroupWeb EmailWire.Com: http://www.emailwire.com.
SOURCE Allegiance Equity Corporation
© 2005-2006 NanoPharmaceuticals.org. All rights reserved. No part of this Internet site may be
reproduced without prior written permission of the copyright holder. Terms & Disclaimer
